Patents Assigned to Fujisawa Pharmaceutical Co., Ltd.
  • Patent number: 7629366
    Abstract: The present invention relates to a compound formula [I]: wherein ?ect., X is bond, —CH2—, ?etc., Y is bond, —O—(CH2)n— (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R1 is hydrogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, R3 is hydrogen or lower alkyl, R4 is hydrogen or lower alkyl, R5 and R8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R6 is hydrogen, lower alkyl, etc., R9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: December 8, 2009
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kouji Hattori, Yasuyo Tomishima, Masashi Imanishi
  • Publication number: 20070123532
    Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 31, 2007
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Kazuhiko Take, Nobukiyo Konishi, Shinji Shigenaga, Natsuko Kayakiri, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Junya Ishida, Masataka Morita
  • Publication number: 20070112037
    Abstract: A compound of the formula (I): wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, etc.; R3 is lower alkoxy, etc.; R4 is hydroxy, etc.; X is O, S, etc.; Y is CH or N; Z is lower alkylene or lower alkenylene; and m is 0 or 1; or salts thereof, which are useful as a medicament.
    Type: Application
    Filed: December 13, 2006
    Publication date: May 17, 2007
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Fumiyuki SHIRAI, Hidenori Azami, Natsuko Kayakiri, Kazuo Okumura, Katsuya Nakamura
  • Publication number: 20060229236
    Abstract: A cyclic tetrapeptide compound of the formula (I): wherein R1 is hydrogen; R2 is lower alkyl, aryl, optionally substituted ar(lower)alkyl, heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl; R3 and R4 are each independently hydrogen, lower alkyl, optionally substituted ar(lower)alkyl, optionally substituted heterocyclic(lower)alkyl or cyclo(lower)alkyl(lower)alkyl, or R3 and R4 are linked together to form lower alkylene or condensed ring, or one of R3 and R4 is linked to the adjacent nitrogen atom to form a ring; R5 is lower alkylene or lower alkenylene, Y is [wherein RY1 is hydrogen, halogen or optionally protected hydroxy, RY2 is hydrogen, halogen, lower alkyl or phenyl, and RY3 is hydrogen or lower alkyl]; R8 is hydrogen or lower alkyl; and n is an integer of 1 or 2, or a salt thereof.
    Type: Application
    Filed: December 27, 2002
    Publication date: October 12, 2006
    Applicant: FUJISAWA PHARMACEUTICAL Co. LTD.
    Inventors: Shigeki Satoh, Yasuharu Urano, Kazuhiko Osoda, Mitsuru Hosaka, Kozo Sawada, Takayuki Inoue, Hiroaki Mori, Shoji Takagaki, Takao Fujimura, Hideaki Matsuoka, Katsuhiko Yoshizawa
  • Publication number: 20060223747
    Abstract: A therapeutic agent for soft tissue sarcoma (particularly synovial sarcoma) contains a histone deacetylase inhibitor (particularly compound of formula I) as an active ingredient
    Type: Application
    Filed: March 8, 2006
    Publication date: October 5, 2006
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Tatsuo Ito, Toshifumi Ozaki, Mamoru Ouchida
  • Publication number: 20060177943
    Abstract: The present invention provides a method of suppressing the nonspecific interaction between molecules, characterized in that in a process to immobilize a molecule onto a solid phase carrier and analyze the specific interaction between the molecule and a molecule that specifically interacts with the molecule on the solid phase, the hydrophobic property of the solid phase surface in the solid phase carrier is regulated, particularly a hydrophilic spacer is interlaid at the time of immobilization of the molecule onto the solid phase carrier, which method makes it possible to suppress the nonspecific interaction between the molecules, and to reduce nonspecific adsorption to the solid phase.
    Type: Application
    Filed: July 30, 2003
    Publication date: August 10, 2006
    Applicants: Reverse Proteomics Research Institute Co., Ltd., Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Akito Tanaka, Tomohiro Terada, Tsuruki Tamura, Takaaki Shiyama, Akira Yamazaki, Minoru Furuya, Masayuki Haramura
  • Publication number: 20060148030
    Abstract: The present invention relates to novel nuclear receptor ERR?3. Although ERR?3 itself lacks a DNA binding domain, it comprises the function of enhancing the transcriptional activation function of arbitrary nuclear receptors, such as ERR, ER, or TR. Moreover, the present inventors found that, like ERR?3, the known proteins ERR?1 and ERR?2 also comprise the function of enhancing the transcriptional activation function of other nuclear receptors. Thus, the present invention provides methods for evaluating the regulatory function of these ERR? subtypes in enhancing the transcriptional activation function of other nuclear receptors, and screening methods based on these evaluation methods.
    Type: Application
    Filed: March 25, 2003
    Publication date: July 6, 2006
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD
    Inventors: Hitoshi Kojo, Kaoru Tajima, Masao Fukagawa, Shintaro Nishimura, Takao Isogai
  • Publication number: 20060135401
    Abstract: The invention relates to a novel method for selecting an immunosuppressive agent with a less thrombocytopenia effect. According to the invention, a method for selecting an immunosuppressive agent which has a potent immunosuppressive activity but a lower thrombocytopenia effect, said method comprising measuring an IL-2 transcription inhibitory activity in a test cell in to which an IL-2 reporter gene has been introduced in the coexistence of an analyte, while measuring a GATA-1 transcription inhibitory activity in the test cell into which a GATA-1 reporter gene has been introduced in the coexistence of an analyte, and comparing both the transcription inhibitory activities, is provided.
    Type: Application
    Filed: July 7, 2003
    Publication date: June 22, 2006
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Takao Fujimura, Hiroaki Mori, Katsuhiko Yoshizawa, Yoko Takata, Ichiro Aramori, Hideaki Matsuoka, Akira Unami, Takahisa Noto
  • Publication number: 20060128770
    Abstract: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.
    Type: Application
    Filed: February 2, 2006
    Publication date: June 15, 2006
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Takayuki Inoue, Takashi Tojo, Masataka Morita, Mitsuru Ohkubo, Kousei Yoshihara, Akira Nagashima
  • Patent number: 7060721
    Abstract: Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: June 13, 2006
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Noriko Oku, legal representative, Chikako Oku, legal representative, Tomohito Oku, legal representative, Hiroshi Kayakiri, Yoshito Abe, Hitoshi Hamashima, Hitoshi Sawada, Naoki Ishibashi, Hiroyuki Setoi, Noritsugu Yamasaki, Takafumi Imoto, Takahiro Hiramura, Teruo Oku, deceased
  • Publication number: 20060100252
    Abstract: The present invention relates to a compound formula [I]: wherein ect., X is bond, —CH2—, etc., Y is bond, —O—(CH2)n— (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R1 is hydrogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, R3 is hydrogen or lower alkyl, R4 is hydrogen or lower alkyl, R5 and R8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R6 is hydrogen, lower alkyl, etc., R9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.
    Type: Application
    Filed: December 16, 2005
    Publication date: May 11, 2006
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Kouji Hattori, Yasuyo Tomishima, Masashi Imanishi
  • Publication number: 20060094007
    Abstract: A method for identifying a pancreatic ductal carcinoma-specific gene made up of the steps of: a) preparing pancreatic ductal cells from a pancreatic ductal carcinoma patient and a normal individual; b) detecting the gene expression in the pancreatic ductal cells prepared from the pancreatic ductal carcinoma patient and the gene expression in the pancreatic ductal cells prepared from the normal individual; c) comparing the gene expression in the pancreatic ductal cells prepared from the pancreatic ductal carcinoma patient with the gene expression in the pancreatic ductal cells prepared from the normal individual; and d) identifying a gene specifically expressed in the pancreatic ductal carcinoma patient and a gene specifically expressed in the normal individual.
    Type: Application
    Filed: May 22, 2003
    Publication date: May 4, 2006
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD
    Inventor: Hiroyuki Mano
  • Patent number: 7029860
    Abstract: The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-? protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-? protein; and therapeutic agents for treating or preventing Alzheimer's diseases comprising a compound that regulates the activity of a protein suppressing or promoting the aggregation or deposition of amyloid-? protein.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: April 18, 2006
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Toshio Ota, Takao Isogai, Tetsuo Nishikawa, Yuri Hio, Mayako Yamazaki, Susumu Satoh, Hiroyuki Arakawa, Masahiko Morita
  • Publication number: 20060063794
    Abstract: The invention provides a method of attenuating graft rejection in a patient undergoing an organ or tissue transplantation procedure. The inventive method involves administering FK778 using a dosing regimen that includes a period of customized administration to achieve or approximate a target whole blood trough level of FK778. The regimen optionally includes administration of a calcineurin inhibitor, such as Tacrolimus, and/or a steroid, and/or an antiviral. Specific preferred quantities of these pharmaceutically-active agents are provided as well as preferred timing and routes of administration. The invention also provides a medical kit for administering FK778. The kit includes printed instructions for administering FK778 to the patient undergoing a graft transplantation procedure according to a dosing regimen containing a period during which the dosage of FK778 is adjusted to deliver an amount of FK778 sufficient to maintain a target whole blood though level of FK778, such as described herein.
    Type: Application
    Filed: September 17, 2004
    Publication date: March 23, 2006
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Karsten Roth, Nasrullah Undre
  • Publication number: 20060035918
    Abstract: A method for treating or prevent acute or chronic asthma is disclosed, comprising administering effect amounts of an FK506 derivative and a ?2-agonist to a human being or an animal.
    Type: Application
    Filed: November 4, 2003
    Publication date: February 16, 2006
    Applicant: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Yoshitaka Hirayama, Yoshihiko Morishita
  • Publication number: 20060014948
    Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.
    Type: Application
    Filed: October 20, 2004
    Publication date: January 19, 2006
    Applicant: Fujisawa Pharmaceutical Co. Ltd.
    Inventors: Kazuhiko Take, Nobukiyo Konishi, Shinji Shigenaga, Natsuko Kayakiri, Hidenori Azami, Yoshiteru Eikyu, Kazuo Nakai, Junya Ishida, Masataka Morita
  • Publication number: 20060009470
    Abstract: The present invention provides a method of specifically potentiating an N-type Ca2+ channel activity, which includes administering, to a subject, a compound of the following formula (I): wherein R1 is lower alkyl, aryl, ar(lower)alkoxy or a heterocyclic group, the above groups being optionally substituted by halogen, R2 is hydrogen atom or lower alkyl, R3 is cyclo(lower)alkyl, aryl or ar(lower)alkyl, the above groups being optionally substituted by halogen, A is —CO—, —SO2— or lower alkylene, and Y shows —CO—, —SO2— or —CONH— (compound (I)), a salt thereof, a prodrug thereof or a solvate thereof; a method for the prophylaxis or treatment of brain disorders such as dementia and amnesia, which includes such administration; and a screening method particularly useful for screening a compound having a similar effect as compound (I).
    Type: Application
    Filed: September 19, 2005
    Publication date: January 12, 2006
    Applicants: Shuji KANEKO, Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Shuji Kaneko, Nobuya Matsuoka
  • Publication number: 20060002923
    Abstract: A recombinant antibody in which at least the constant regions in the heavy chain and the light chain have been converted into human-origin regions and which inhibits the binding of an integrin recognizing the RGD sequence to osteopontin or its fragment and inhibits the binding of an integrin recognizing the SVVYGLR sequence or a sequence corresponding thereto to osteopontin or its fragment. This antibody is useful as a remedy for autoimmune diseases and a remedy for rheumatism or rheumatoid arthritis. Thus, a method of treating autoimmune diseases, rheumatism or rheumatoid arthritis is provided. This osteopontin antibody is useful in a diagnostic for rheumatism and a method of diagnosing rheumatism too.
    Type: Application
    Filed: September 25, 2002
    Publication date: January 5, 2006
    Applicants: IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Toshimitsu Uede, Shigeyuki Kon, Nobuchika Yamamoto, Hirofumi Higuchi, Masaharu Torikai, Yoshiyuki Tokieda, Toshihiro Nakashima, Hiroaki Maeda
  • Patent number: 6979461
    Abstract: An object of the present invention is to provide a method for producing a liposome preparation having excellent rapid action and excellent redispersion into aqueous medium. The present invention provides a method for producing a liposome preparation by vacuum drying wherein liposome condensed solution, which is obtained by removing solvent from liposome solution, is subjected to vacuum drying without freezing while bubbling the condensed solution or after the condensed solution is bubbled.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: December 27, 2005
    Assignee: Fujisawa Pharmaceutical Co., Ltd.
    Inventors: Kazumi Ohtomo, Hajime Konno, Akihiro Kasai
  • Publication number: 20050282865
    Abstract: This invention provides a novel neurotrophic factor production promoter containing N-acetyl-L-pipecolic acid or a pharmaceutically acceptable salt thereof as an active ingredient, which can be used for the prophylaxis or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, spinal injury, Huntington's disease, cerebral infarction, head trauma, multiple sclerosis, amyotrophic lateral sclerosis, diabetic or drug-induced peripheral neuropathy and retinal neuropathy, and the like.
    Type: Application
    Filed: October 10, 2003
    Publication date: December 22, 2005
    Applicant: FUJISAWA PHARMACEUTICAL CO., LTD.
    Inventors: Shoei Furukawa, Atsumi Nitta